EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

Fuat Bicer, Catrina Kure, Anil A Ozluk, Bassel F El-Rayes, Mehmet Akce iD

Current Oncology · 07.11.2023 · 30 (11) · 9789-9812

DOI: 10.3390/curroncol30110711 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 07.11.2023. Verfasst von Fuat Bicer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerged as novel therapy options for advanced HCC. Only one third of patients achieve an objective response with ICI-based therapies due to primary resistance or acquired resistance. The liver tumor microenvironment is naturally immunosuppressive, and specific mutations in cell signaling pathways allow the tumor to evade the immune response. Next, gene sequencing of the tumor tissue or circulating tumor DNA may delineate resistance mechanisms to ICI-based therapy and provide a rationale for novel combination therapies. In this review, we discuss the results of key clinical trials that have led to approval of ICI-based therapy options in advanced HCC and summarize the ongoing clinical trials. We review resistance mechanisms to ICIs and discuss how immunotherapies may be optimized based on the emerging research of tumor biomarkers and genomic alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyBiomarkers, TumorTumor Microenvironment

Stichwörter der Autor:innen

HCCLAG3PD1PDL1TIGITTIM3immunotherapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Hematology Oncology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA.
  • Department of Medicine, Northside Hospital-Gwinnett, Lawrenceville, GA 30046, USA.
  • Division of Hematology Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35233, USA.

ORCID-Profile: Mehmet Akce

Zitieren

APA

Bicer, F., Kure, C., Ozluk, A. A., El-Rayes, B. F., & Akce, M. (2023). Advances in Immunotherapy for Hepatocellular Carcinoma (HCC). Current Oncology, 30(11), 9789-9812. https://doi.org/10.3390/curroncol30110711

Vancouver

Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC). Current Oncology. 2023;30(11):9789-9812. doi:10.3390/curroncol30110711

BibTeX
@article{Bicer2023,
  author = {Bicer, Fuat and Kure, Catrina and Ozluk, Anil A and El-Rayes, Bassel F and Akce, Mehmet},
  title = {Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {11},
  pages = {9789--9812},
  doi = {10.3390/curroncol30110711}
}
Kostenlos starten →